ITRMF
Iterum Therapeutics plcCompany with tickers: ITRM
CIK
1659323
CUSIP
G6333L200
Shares Outstanding
53,291,578
13F Activity (30d)
9 filings
8 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $390,000 | USD | 2025-09-30 | 10-Q | 2025-11-14 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $8,121,000 | USD | 2025-09-30 | 10-Q | 2025-11-14 |
| Research & Development | $1,261,000 | USD | 2025-09-30 | 10-Q | 2025-11-14 |
| Operating Income | $-7,731,000 | USD | 2025-09-30 | 10-Q | 2025-11-14 |
| Net Income | $-8,979,000 | USD | 2025-09-30 | 10-Q | 2025-11-14 |
| EPS (Basic) | $-0.20 | USD/shares | 2025-09-30 | 10-Q | 2025-11-14 |
| EPS (Diluted) | $-0.20 | USD/shares | 2025-09-30 | 10-Q | 2025-11-14 |